In recent years, there has been an exponential increase in the development and approval of therapeutic proteins, oligonucleotides, and conjugates, transforming the landscape of modern medicine. Advances in biotechnology, genomics, and molecular biology have driven this surge, enabling the creation of highly targeted therapies for a wide range of conditions, including cancer, rare genetic disorders, and autoimmune diseases.
Therapeutic proteins, such as monoclonal antibodies and enzymes, offer precise mechanisms of action and have become essential in treating chronic and life-threatening illnesses. Oligonucleotides—including antisense therapies, small interfering RNA (siRNA), and mRNA-based treatments—are revolutionizing medicine by targeting genetic material directly, enabling breakthroughs in gene therapy and personalized medicine. Meanwhile, conjugates, such as antibody-drug conjugates (ADCs), combine the specificity of biologics with the potency of small molecules, allowing for targeted delivery of therapies with reduced side effects.
As a small virtual pharmaceutical company, Brick42 has the agility to transition quickly and effectively to support generic companies entering these advanced therapeutic markets. We are actively engaged in multinational research projects focused on novel conjugates, innovative vectors for existing therapies, and the development of protein and oligonucleotide drugs. This strategic shift allows us to offer specialized expertise and flexible solutions, helping our partners navigate the complex challenges of bringing these groundbreaking therapies to market.